急性肺损伤（ALI）迄今尚无安全有效的药物干预手段。肺血管内皮细胞损伤是ALI的关键病理生理机制，他汀类具有逆转血管内皮细胞损伤的作用，但用于治疗ALI仍受限于疗效不确定、不良反应多等问题，亟待研究进一步解决。课题组前期构建的ICAM-1单抗纳米载体，初步证明具有ALI血管内皮细胞的靶向作用，并可高效包载他汀类，提示通过该纳米载体可将他汀类靶向ALI血管内皮细胞。基于此，课题组继续构建ICAM-1单抗他汀纳米载体，研究其理化性质和药物靶细胞和靶组织分布。进一步建立ALI血管内皮细胞和动物模型，从细胞增殖、炎症因子等方面评价ICAM-1单抗他汀纳米载体对ALI的改善作用。最后通过研究ICAM-1单抗纳米载体转运他汀类进入靶细胞与CAM-介导机制的相关性，明确纳米载体靶向转运药物的关键机制。本课题的开展旨在为建立安全、高效的ALI 他汀靶向治疗新方案提供直接的科学依据。

Acute lung injury (ALI) is a disease without safe and effective drug intervention methods till now. Pulmonary vascular endothelial cell injury is the key pathophysiology for ALI. Statins have demonstrated their abilities to reverse the process of vascular endothelial cell injury, but the problems needing to further study are uncertain drug efficacy and adverse drug reactions when ALI treated with statins. In our previous study, ICAM-1 monoclonal antibody (anti-ICAM) nanocarriers which were possibly targeting to ALI vascular endothelial cell were prepared, and demonstrated with high drug entrapment efficiency for stains. From these results，we can infer that stains can be successfully targeted to ALI vascular endothelial cell mediated by anti-ICAM nanocarriers. In present study, anti-ICAM stain nanocarriers were continually prepared, and there physicochemical properties and drug levels in targeting cells and tissue were determined at first. Secondly, ALI vascular endothelial cells and animal models were established, and the effect of anti-ICAM stain nanocarriers on ALI including the factors cell proliferation, inflammatory factors, etc, were evaluated thereafter. Finally, the key mechanism for anti-ICAM-1 nanocarrier transporting statin into target cells, which might be related with CAM- mediated passway, were studied. In all, this study may provide a safe, efficient and new stain targeting therapy method for ALI.